How Have Orphan Drugs Changed the Specialty Landscape Over the Past Few Years?

Joy Gilbert, Vice President, Operations, US Bioservices, a part of AmerisourceBergen, talks about the impact orphan drugs have had on the specialty pharmaceutical industry.

Gilbert: I think orphan drugs have made significant changes to the specialty pharmacy landscape recently, specifically because some of these drugs are coming to disease states that have never had treatment before and also have extremely small patient population.

That requires us as specialty pharmacies to really be targeted and focused on those specific needs of those small patient populations, which are unique from other patient populations that we have dealt with in the past.